|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 118.3 USD | +2.04% |
|
-0.36% | +18.97% |
| 02/07 | Moderna, Pfizer-BioNTech COVID-19 Vaccine Patent Legal Battle Gets Mixed UK Ruling | MT |
| 02/07 | Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case | MT |
WASHINGTON (Reuters) - The price hike for Moderna Inc COVID-19 shots is hard to justify, White House spokesperson Karine Jean-Pierre said on Thursday.
Moderna is considering pricing its vaccine at $110 to $130 per dose in the United States when it shifts from government contracting to commercial distribution, the company's chief executive, Stephane Bancel, told the Wall Street Journal on Monday.
(Reporting By Jeff Mason and Jarrett Renshaw; Editing by Leslie Adler)
| 1st Jan change | Capi. | |
|---|---|---|
| +18.97% | 4.53TCr | |
| +41.98% | 4.04TCr | |
| -10.06% | 3.79TCr | |
| +31.15% | 3.18TCr | |
| -7.79% | 2.77TCr | |
| +13.32% | 2.65TCr | |
| +43.05% | 1.4TCr | |
| +31.28% | 1.24TCr | |
| -7.41% | 1.13TCr | |
| -15.54% | 1.03TCr |
MODERNA, INC. 
